Conditions: Liver Transplantation Postreperfusion Syndrome
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 62
Healthy volunteers: no

Brief summary:
This study intends to see the effect of nafamostat on the attenuation of postreperfusion syndrome (PRS) that frequently occurs during liver transplantation.

Detailed description:

Arms:
arm 1: The Nafamostat mesilate group received 0.2 mg/kg of nafamostat mesilate intravenously 1 min before reperfusion of the liver graft. arm 2: The control group received 10 ml of normal saline (same volume as nafamostat)intravenously 1 min before reperfusion of the liver graft.

Interventions: intervention 1: Nafamostat intervention 2: Normal saline
Intervention descriptions: intervention 1: 0.2 mg/kg as bolus 1 minute before reperfusion intervention 2: 10 ml of normal saline

Protocol document: